Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, MD, Radhakrishnan Ramchandren, MD, Michael Maris, MD, Alexander M. Lesokhin, MD, Gottfried R. von Keudell, MD PhD, Bruce D. Cheson, MD, Jeff Zonder, MD, Erlene K. Seymour, MD, Tina Catalano, MSc, Gloria H. Y. Lin, PhD, Bob Uger, PhD, Penka S. Petrova, PhD, Kathleen Roberge, ANP, MSc, Yaping Shou, MDPhD, Swami P. Iyer, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136607

Published: 2020

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-136198

Published: 2020

Journal Articles

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew H. Taylor, MD, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Theresa Thompson, Robert A. Uger, PhD, Yaping Shou, MD PhD, Oleg E. Akilov, MD

Blood (2018) 132 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2018-99-116915

Published: 2018

Journal Articles

Healthcare Burden of Patients with Follicular Lymphoma (FL) in Routine Clinical Care in the United States

Aaron Galaznik, MD, Jill A Bell, PhD, Laurie Hamilton, MS, Augustina Ogbonnaya, MPH, Kristin Hennenfent, PharmD, Michael T. Eaddy, PharmD, PhD, Yaping Shou, MD PhD

Blood (2017) 130 (Supplement 1): 2183.

https://doi.org/10.1182/blood.V130.Suppl_1.2183.2183

Published: 2017

Journal Articles

Survival Outcomes after First-Line Therapy in Follicular Lymphoma Patients Treated with Bendamustine and Rituximab Vs Other Rituximab Combinations in the United States

Aaron Galaznik, MD, Jill A Bell, PhD, Laurie Hamilton, MS, Augustina Ogbonnaya, MPH, Kristin Hennenfent, PharmD, Michael T. Eaddy, PharmD, PhD, Yaping Shou, MD PhD

Blood (2017) 130 (Supplement 1): 2184.

https://doi.org/10.1182/blood.V130.Suppl_1.2184.2184

Published: 2017

Journal Articles

Economic Impact and Healthcare Utilization in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Routine Clinical Care in the United States (US) - a Claims Database Study

Aaron Galaznik, MD, Jill A Bell, PhD, Laurie Hamilton, MS, Augustina Ogbonnaya, MPH, Kristin Hennenfent, PharmD, Michael T. Eaddy, PharmD, PhD, Yaping Shou, MD PhD

Blood (2017) 130 (Supplement 1): 2185.

https://doi.org/10.1182/blood.V130.Suppl_1.2185.2185

Published: 2017

Journal Articles

Treatment Patterns in Newly Treated and Relapse/Refractory Patients with Follicular Lymphoma in Routine Clinical Care — a United States Electronic Medical Record Database Study

Aaron Galaznik, MD, Jill A Bell, PhD, Laurie Hamilton, MS, Augustina Ogbonnaya, MPH, Kristin Hennenfent, PharmD, Michael T. Eaddy, PharmD, PhD, Yaping Shou, MD PhD

Blood (2017) 130 (Supplement 1): 4059.

https://doi.org/10.1182/blood.V130.Suppl_1.4059.4059

Published: 2017

Journal Articles

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Keith Pratz, MD, Mark J. Levis, MD, John C Morris, MD, Trisha Wise-Draper, MD PhD, Moshe Levy, MD, Dale L. Bixby, Patrick Burke, MD, Daniela Hernandez, MD, Kate Stumpo, BA, Karuppiah Kannan, Emily Sheldon-Waniga, PhD, Shining Wang, MD, Steven Zhang, PhD, Yaping Shou, MD PhD, Jessica K. Altman, MD, Jason Kaplan, MD, Olga Frankfurt, MD

Blood (2017) 130 (Supplement 1): 2622.

https://doi.org/10.1182/blood.V130.Suppl_1.2622.2622

Published: 2017

Journal Articles

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

Jason Kaplan, MD, Leo I. Gordon, MD, Alessandro Rambaldi, MD Prof, Giuseppe Gritti, MD, Rakesh Popat, MD PhD, Howard A. Burris, MD, Manish R Patel, MD, Sumit Madan, MD, Ian Chau, MD, John A. Radford, MD, Swami P. Iyer, MD, Jaime Perez De Oteyza, MD, Pier Luigi Zinzani, MD, Shining Wang, MD, Emily Sheldon-Waniga, PhD, Kate Stumpo, BA, Yaping Shou, MD PhD, Cecilia Carpio, MD, Francesc Bosch, MD

Blood (2017) 130 (Supplement 1): 1554.

https://doi.org/10.1182/blood.V130.Suppl_1.1554.1554

Published: 2017

Journal Articles

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Jason B Kaplan, MD, Dale L. Bixby, MD, John C Morris, MD, Olga Frankfurt, MD, Jessica Altman, Trisha Wise-Draper, MD PhD, Patrick W. Burke, MD, Sabrina Collins, BS, Karuppiah Kannan, PhD, Ling Wang, PhD, Stephanie Faucette, PharmD, PhD, Benjamin Lee, MD PhD, Yaping Shou, MD PhD, Mark J. Levis, MD PhD, Keith W. Pratz, MD

Blood (2016) 128 (22): 2834.

https://doi.org/10.1182/blood.V128.22.2834.2834

Published: 2016

Journal Articles

Systematic Review of Therapy Used in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Aaron Galaznik, MD, Jill A Bell, PhD, Meredith M Hoog, MPH, Michael E Stokes, MPH, Anna W Steenrod, MPH, Kevin B Knopf, MD, Brian Seal, RPh, MBA, PhD, Yaping Shou, MD PhD

Blood (2016) 128 (22): 3562.

https://doi.org/10.1182/blood.V128.22.3562.3562

Published: 2016

Journal Articles

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Blood (2016) 128 (22): 624.

https://doi.org/10.1182/blood.V128.22.624.624

Published: 2016

Journal Articles

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Adam M. Petrich, MD, Leo I. Gordon, MD, Jeffrey R. Infante, MD, Sumit Madan, MD, Francis J. Giles, MD, Halla S. Nimeiri, MBBS, Jason B. Kaplan, MD, Kate Stumpo, Bin Zhang, ScD, Stephanie Faucette, PharmD, PhD, Yaping Shou, MD PhD, Kent C. Shih, MD

Blood (2015) 126 (23): 2693.

https://doi.org/10.1182/blood.V126.23.2693.2693

Published: 2015

Journal Articles

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Shaji K. Kumar, William I. Bensinger, Todd M. Zimmerman, Craig B. Reeder, James R. Berenson, Deborah Berg, Ai-Min Hui, Neeraj Gupta, Alessandra Di Bacco, Jiang Yu, Yaping Shou, Ruben Niesvizky

Blood (2014) 124 (7): 1047–1055.

https://doi.org/10.1182/blood-2014-01-548941

Published: 2014

Includes: Supplemental data

Journal Articles

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Andreas Hochhaus, Giuseppe Saglio, Richard A. Larson, Dong-Wook Kim, Gabriel Etienne, Gianantonio Rosti, Carmino De Souza, Mineo Kurokawa, Matt E. Kalaycio, Albert Hoenekopp, Xiaolin Fan, Yaping Shou, Hagop M. Kantarjian, Timothy P. Hughes

Blood (2013) 121 (18): 3703–3708.

https://doi.org/10.1182/blood-2012-04-423418

Published: 2013

Journal Articles

Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

Sarit Assouline, Julie E. Chang, MD, Bruce D. Cheson, MD, Robert Rifkin, MD, Solomon Hamburg, MD, PhD, Ruben Reyes, MD, Ai-Min Hui, MD, PhD, Jiang Yu, Neeraj Gupta, PhD, Alessandra Di Bacco, PhD, Yaping Shou, Peter Martin, MD

Blood (2012) 120 (21): 3646.

https://doi.org/10.1182/blood.V120.21.3646.3646

Published: 2012

Journal Articles

The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up

Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Gabriel Etienne, MD, PhD, Carmino De Souza, MD, PhD, Mineo Kurokawa, MD, Matt Kalaycio, MD, Giuseppe Saglio, MD, Richard A. Larson, MD, Hagop M. Kantarjian, Albert Hoenekopp, MD, Yaping Shou, MD, PhD, Richard Yu, Rick E. Blakesley, PhD, Gianantonio Rosti, MD, Andreas Hochhaus, MD

Blood (2011) 118 (21): 2755.

https://doi.org/10.1182/blood.V118.21.2755.2755

Published: 2011

Journal Articles

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Blood (2011) 118 (21): 3770.

https://doi.org/10.1182/blood.V118.21.3770.3770

Published: 2011

Journal Articles

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Hagop M. Kantarjian, Francis J. Giles, Kapil N. Bhalla, Javier Pinilla-Ibarz, Richard A. Larson, Norbert Gattermann, Oliver G. Ottmann, Andreas Hochhaus, Jerald P. Radich, Giuseppe Saglio, Timothy P. Hughes, Giovanni Martinelli, Dong-Wook Kim, Yaping Shou, Neil J. Gallagher, Rick Blakesley, Michele Baccarani, Jorge Cortes, Philipp D. le Coutre

Blood (2011) 117 (4): 1141–1145.

https://doi.org/10.1182/blood-2010-03-277152

Published: 2011

Journal Articles

Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).

Andreas Hochhaus, MD, Giuseppe Saglio, MD, PhD, Richard A. Larson, MD, Dong-Wook Kim, MD, PhD, Ian W. Flinn, MD, PhD, Yeow-Tee Goh, MBBS, MD, Pedro Enrique Dorlhiac-Llacer, MD, Kimmo Porkka, MD, PhD, Mineo Kurokawa, MD, PhD, Carmino DeSouza, MD, PhD, Yaping Shou, MD, PhD, Neil J. Gallagher, MD, PhD, Ariful Haque, Hagop Kantarjian, MD, Timothy P. Hughes, MD, MBBS

Blood (2010) 116 (21): 3431.

https://doi.org/10.1182/blood.V116.21.3431.3431

Published: 2010

NARROW

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

Healthcare Burden of Patients with Follicular Lymphoma (FL) in Routine Clinical Care in the United States

Survival Outcomes after First-Line Therapy in Follicular Lymphoma Patients Treated with Bendamustine and Rituximab Vs Other Rituximab Combinations in the United States

Economic Impact and Healthcare Utilization in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Routine Clinical Care in the United States (US) - a Claims Database Study

Treatment Patterns in Newly Treated and Relapse/Refractory Patients with Follicular Lymphoma in Routine Clinical Care — a United States Electronic Medical Record Database Study

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Systematic Review of Therapy Used in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only